Important information about COVID-19

For more information about COVID-19, please click here

TAKE THE MYSTERY OUT OF YOUR GLUCOSE LEVELS

With the FreeStyle Libre 2 system, you can check your glucose with a painless*1,2 scan instead of fingersticks.

Now You Know

NOW APPROVED: The FreeStyle Libre 3 app‡  in iOS for daily insulin users
NOW APPROVED: The FreeStyle Libre 3 app‡  in iOS for daily insulin users
NOW APPROVED: The FreeStyle Libre 3 app‡  in iOS for daily insulin users

Introducing the FreeStyle Libre 3 system, 
the latest addition to our family of products.

 

 

Try CGM with the
FreeStyle Libre 2 system
for FREE

Track your glucose levels on the FreeStyle Libre 2
app§ and unlock insights about what impacts your
glucose levels3

Get 14 days of guided
support that can help
lower your A1c levels*4,5

Why CGM?

Make more informed decisions:

  • The FreeStyle Libre 2 system automatically tracks your glucose levels day and night using a small sensor worn on the back of the upper arm and an app§ or readerII that lets you view your glucose levels at any time#

  • Unlike a blood glucose monitor, which only gives you a current glucose reading, CGM shows additional insights into where your glucose level was, currently is, and where it’s headed

For illustrative purposes only. Not actual patient data.

Discover more affordable CGM systems**††6

  • Most commercially insured patients pay between $0 to $60 per month for FreeStyle Libre 2 or FreeStyle Libre 14 day sensors,‡‡§§6 and no more than $65 for a FreeStyle Libre 2 reader (at participating pharmacies)IIII6

  • When you use the no-cost FreeStyle Libre 2 app§, there is no need to fill the readerII

  • More Medicare patients are now eligible for coverage.¶¶ Learn more here

Know it all from your phone§##

The FreeStyle Libre 2 app§ and the FreeStyle LibreLink app## let you scan your sensors using a compatible smartphone instead of a reader.II***††† You can download the FreeStyle Libre 2 app§ from the Apple App Store or Google Play for free.

Sign up to stay in the know

You’ll get tips on managing your diabetes, product news, offers, and more!

Please provide first name Please provide first name Please provide first name
Please provide last name Please provide last name Please provide last name
Please enter a valid email Please provide your email.

All fields are required unless noted otherwise.

By clicking "SIGN UP", I agree that: (1) The information I’ve provided will be used by Abbott and its contracted third parties only, to email me helpful information on diabetes and related treatments, products and services, and for marketing and information purposes in accordance with Abbott’s privacy policy at https://www.abbott.com/privacy-policy.html. (2) Abbott will not sell or transfer my name or contact information to any third party for its marketing use. (3) I am at least 18 years of age.

Medicare coverage is available for the FreeStyle Libre 2 system if the FreeStyle Libre 2 reader is used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.

Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.

† Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

‡ or ♢ Eligible patients will receive one (1) FreeStyle Libre 2 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with Type 1 and Type 2 diabetes; it is not available for patients with gestational diabetes. Only patients ages 18 and older are eligible to sign up and receive an offer for the FreeStyle Libre 2 sensor and patients ages 4-17 are eligible to receive an offer for the FreeStyle Libre 2 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs or residents of Massachusetts, Puerto Rico and other US territories. The free FreeStyle Libre 2 sensor is provided as a sample and is limited to one NDC per eligible person. The FreeStyle Libre 2 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.

§ The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.

II The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

¶ Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours.

# Glucose readings are not available during 1-hour warm-up, when sensor is too hot or too cold, or when you see an error, "LO" or "HI" message, or no current glucose reading.

** Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

†† Based on a comparison of list prices of the FreeStyle Libre 14 day system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

‡‡ Based on prescription claims for commercially insured patients using the FreeStyle Libre 14 day system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 14 day system requires a prescription.

§§ Based on prescription claims for commercially insured patients using the FreeStyle Libre 2 system. Does not include Medicare, Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.

IIII Benefits for FreeStyle Libre 2 sensors apply to two FreeStyle Libre 2 sensors per month. Benefits for FreeStyle Libre 2 reader apply to one FreeStyle Libre 2 reader. Void where prohibited by law. Abbott may modify, rescind, or revoke these benefits at any time without notice. Offer available to commercially insured patients only. These benefits are not available to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. For Massachusetts residents, only those patients responsible for the full cost of the product may be eligible to receive these benefits. These benefits are only available at participating pharmacies, which are subject to change without notice. The actual amount a patient pays may vary. The FreeStyle Libre 2 system requires a prescription.
 
¶¶ On May 8, 2020, CMS published a second interim final rule with comment, CMS-5531-IFC, that expanded the non-enforcement of clinical indications of coverage to therapeutic continuous glucose monitors (CGMs). (www.govinfo.gov/content/pkg/FR-2020-05-08/pdf/2020-09608.pdf) The Durable Medical Equipment Medicare Administrative Contractors (DME MAC) subsequently issued guidance on the IFC policies, including discussing that clinical indications for coverage in the therapeutic CGM LCD (Glucose Monitors, L33822) will not be enforced. See “CMS Issues Interim Final Rules with Comment (CMS-1744-IFC & CMS-5531-IFC) – COVID-19 Public Health Emergency – Revised May 21, 2020.” (www.cgsmedicare.com/jc/pubs/news/2020/05/​cope1733) Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.

## The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle LibreLink app requires registration with LibreView.

*** Medicare coverage is available for FreeStyle Libre 14 day systems for cell phone use if FreeStyle LibreLink is used in conjunction with the FreeStyle Libre 14 day readers. Patients must meet Medicare eligibility coverage criteria LCD L33822 (February 2022). Local Coverage Article: Glucose Monitor Policy Article (A52464), February 2022.
 

††† The FreeStyle LibreLink app and the FreeStyle Libre 14 day reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

References: 1. Al Hayek, Ayman A., Robert A. Asirvatham, and Mohamed A. Al Dawish. “Acceptability of the FreeStyle Libre Flash Glucose Monitoring System: The Experience of Young Patients With Type 1 Diabetes.” Clinical Medical Insights: Endocrinology and Diabetes 13 (March 2020): 1-7. https://doi.org/10.1177/1179551420910122. The study included patients between ages 13 and 18 years. 2. Haak, Thomas, et al. "Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-treated Type 2 Diabetes: a Multicentre, Open-label Randomised Controlled Trial." Diabetes Therapy 8, no. 1 (February 2017): 55-73. https://doi.org/10.1007/s13300-016-0223-6. 3. FreeStyle Libre 2 User’s Manual. 4. Kroeger, Jens, Peter Fasching, and Helene Hanaire. "Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes." Diabetes Therapy 11, no. 1 (January 2020): 279-291. https://doi.org/10.1007/s13300-019-00741-9. 5. Evans, Mark, et al. "The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: a Meta-analysis of Clinical Trials and Real-world Observational Studies." Diabetes Therapy 11, no. 1 (January 2020): 83-95. https://doi.org/10.1007/s13300-019-00720-0. 6. Data on File. Abbott Diabetes Care.
 

Abbott supports patient access to the FreeStyle Libre family of products through a variety of programs, including trial offers, that may reduce the out-of-pocket amounts that patients must pay. The actual amount that a patient may pay may vary or change based on factors such as the duration of the program, product insurance coverage status, state of residence, or other eligibility limitations. Abbott may modify, rescind, or revoke these programs at any time without notice.

ADC-12211 v24.0 07/22

Important Safety Information

FreeStyle Libre 14 day system: Failure to use FreeStyle Libre 14 day system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

The product images are for illustrative purposes only.

The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the United States.

ADC-29111 v11.0 05/22

Cookie Policy.

FreeStyle Libre uses cookies to give you the best possible service. By using our website, you consent to the use of cookies. More on this